Theratechnologies (TSE:TH) has released an update.
Theratechnologies Inc. faces a potential early 2025 supply disruption for its EGRIFTA SV product due to a temporary shutdown of its contract manufacturer’s facility after an FDA inspection. The company is actively working with the FDA and other stakeholders to resume production and has implemented inventory management strategies to minimize patient impact. Despite these efforts, Theratechnologies anticipates a revenue shortfall of approximately $1.6 million for the fiscal year 2024.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
